2023-506183-13-00招募中2 期
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter, Parallel-Group Study to Investigate the Safety, Tolerability, and the Effect of RO7269162 on Amyloid and Non-Amyloid Disease-Related Biomarkers following Daily Oral Administration in Participants at Risk for or at the Prodromal Stage of Alzheimer’s Disease
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 186
- 试验地点
- 47
- 主要终点
- 1. Nature, incidence, severity, and outcome of AEs
研究概览
简要总结
- To investigate the safety and tolerability of daily oral dosing of RO7269162 and to assess the effect of daily oral dosing of RO7269162 on brain amyloid accumulation
研究设计
- 分配方式
- Na
- 主要目的
- Follow-up
- 盲法
- Double (Investigator, Subject)
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •Body Mass Index (BMI) between 18 to 35 kg/m2 inclusive, at screening
- •Participants must be either cognitively unimpaired or with a diagnosis of MCI due to AD, according to the NIA – AA workgroups on diagnostic guidelines for AD, and/or according to the updated NIA-AA research framework
- •Clinical Dementia Rating-Global Score (CDR-GS) of 0 or 0.5
- •Positive amyloid PET scan based on a cut-off of ≥24 CL units
- •Availability of a person (referred as a “study partner” throughout the protocol) who: (a) has frequent and sufficient contact (e.g., minimum twice a week in-person, via telephone, video calls, by e-mail or other electronic means) with the participant, and is willing and able to provide accurate information regarding the participant’s cognitive and functional abilities, signs the necessary ICF(s), and has sufficient cognitive capacity to accurately report on the participant’s cognitive and functional abilities; (b) is in sufficient good general health to have a high likelihood of maintaining the same level of interaction with the participant and participation in study procedures throughout the duration of the study; and (c) is fluent in the language of the tests used at the study site. Please note that the study partner does not need to be a family member. Every effort should be made to keep the same study partner throughout the study.
- •In case of treatment with symptomatic AD medications, dosing regimen must be stable for at least eight weeks prior to first IMP intake
排除标准
- •Any medical history or evidence of a condition other than AD that may affect cognition
- •History or presence of significant cardiovascular conditions and/or significant hematological disease
- •History or presence of chronic kidney disease and/or impaired hepatic function
- •Uncontrolled/poorly controlled diabetes
- •History of or activate inflammatory bowel disease
- •Have received any passive or active immunotherapy (immunoglobulin) or other long-acting biologic agent that is under evaluation or approved to prevent or postpone cognitive decline administered within 1 year prior to first IMP intake, and/or any other investigational treatment within five half-lives or 16 weeks prior to screening, whichever is longer.
研究组 & 干预措施
FLUTEMETAMOL (18F)
Auxiliary
干预措施: FLUTEMETAMOL (18F) (Drug)
FLORBETABEN (18F)
Auxiliary
干预措施: FLORBETABEN (18F) (Drug)
RO7269162, RO7269162, RO7269162
Test
干预措施: RO7269162 (Drug)
Placebo RO7269162
Placebo
干预措施: Placebo RO7269162 (Drug)
结局指标
主要结局
1. Nature, incidence, severity, and outcome of AEs
1. Nature, incidence, severity, and outcome of AEs
2. Changes from baseline in vital signs, ECG parameters, Columbia-Suicide Severity Rating Scale (C-SSRS) and safety laboratory findings
2. Changes from baseline in vital signs, ECG parameters, Columbia-Suicide Severity Rating Scale (C-SSRS) and safety laboratory findings
3. Change from baseline in brain amyloid load, as measured by amyloid PET scan
3. Change from baseline in brain amyloid load, as measured by amyloid PET scan
次要结局
- 1. Change from baseline in Aβ37, Aβ38, Aβ40 and Aβ42 in CSF and Aβ40 and Aβ42 in plasma
- 2. Plasma concentrations of RO7269162 (and its metabolite[s] as appropriate)
- 3. CSF concentrations of RO7269162 (and its metabolite[s] as appropriate)
研究者
Trial Information System - TISL
Scientific
F. Hoffmann-La Roche AG
研究点 (47)
Loading locations...
相似试验
已完成
1 期
A Study to Evaluate Single Doses of Alpha-0261 in Healthy Adult VolunteersNCT07279636AlphaMol Science Ltd. (Shanghai)55
招募中
2 期
A Study to Assess the Efficacy, Safety, and what the body does to RO7837195 in Participants with Moderately to Severely Active Ulcerative Colitis2025-520690-39-00Genentech Inc.84
招募中
1 期
A First-in-human Trial of GRT7041 in Healthy ParticipantsNCT07289776Grünenthal GmbH70
招募中
3 期
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 DiabetesType 2 Diabetes MellitusNCT07351058Hoffmann-La Roche1,600
招募中
3 期
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 DiabetesNCT07351045Hoffmann-La Roche2,000